Skip to main content
Equibles

VRAX · Virax Biolabs Group Ltd · Metrics

Track VRAX — free

Use VRAX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRAX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.37 -0.03 (-2.14%) At close · Oct 20
Rebalance outlook locked
Market Cap
$1.91M
Shares
1.34M
Volume · Oct 20 14.06K Avg daily vol (3M) 393.62K

VRAX metrics

39 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.37
Market cap
$1.91M

Price action

20 metrics
Price change (1W)
-24.3%
Price change (30D)
-39.4%
Price change (3M)
-64.0%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
212.8%
Annualized volatility (3M)
87.3%
Beta
—
RSI (14D)
24.6
Price vs SMA 50
-43.7%
Price vs SMA 200
—
Avg volume (3M)
398,248
Relative volume
0.0
Average dollar volume
$1.20M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.3
reciprocal yield 380.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
61.9%
Operating margin
-51,515.2%
Trailing 12 months
Net margin
-40,439.1%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$327.05

Growth

11 metrics
Revenue growth YoY
+96.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-86.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+13.2%
Revenue CAGR (5Y)
-36.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-66.3%
Return on assets
-60.3%
Debt / equity
—
Current ratio
10.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
10.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$6.44M
Total assets
$8.32M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
2
13F filer change QoQ
-2
Institutional ownership
2.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-28.3%
Holder tenure
1.0
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.5%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
26 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1885827 CUSIP G9495L133 Visit website Investor relations